Valuation Trading Multiples & Precedent Transactions: Prophylactic Vaccine Manufacturing Companies
Valuation benchmarks for Prophylactic Vaccine Manufacturing Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Prophylactic Vaccine Manufacturing Companies Market Context & Valuation Drivers
Companies in this trading comparable group are public manufacturers and suppliers of human prophylactic vaccines. They integrate R&D, GMP biologics production, and cold-chain distribution to deliver routine immunizations across multiple infectious disease categories. Revenue is driven by dose volumes and average selling prices through national tenders and commercial channels. They are comparable for valuation benchmarks given similar product portfolios, regulatory requirements, capital intensity, and procurement dynamics shaping growth and margin profiles.
These businesses develop viral and bacterial vaccines spanning pneumococcal conjugate, HPV, influenza, meningococcal, rabies, and rotavirus. Core capabilities include antigen scale-up and conjugation chemistry, adjuvant formulation, sterile fill‑finish, quality control, and batch release under GMP. They run clinical trials and regulatory submissions, and operate warehousing, customs clearance, and cold‑chain logistics for broad distribution, with some diversification into plasma products, recombinant proteins, and monoclonal antibodies to leverage manufacturing platforms and improve utilization.
Primary customers include national immunization programs and public health agencies, hospitals and clinics, and vaccine distributors/pharmacies. Key valuation drivers include dose volumes and tender wins, average selling prices, revenue growth across geographies, gross margin from product mix and manufacturing yields, capacity utilization of fill‑finish lines, and pipeline advancement/approvals. Analysts also monitor contract duration, seasonal demand profiles, and cold‑chain distribution efficiency as indicators of predictability and scalability.
2. Valuation Analysis: Public Trading Comps & Multiples for Prophylactic Vaccine Manufacturing Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Prophylactic Vaccine Manufacturing Companies sector
Comparable group 1: Prophylactic Vaccine Manufacturing Companies
Chongqing Zhifei
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of warehousing, customs clearance, and batch release services for imported goods through their airport facilities; also offers logistics, distribution, and product promotion services.
- Key Products:
- Warehousing: Offers storage solutions for various goods at their facilities
- Customs Clearance: Facilitates regulatory clearance for imported products
- Batch Release: Manages scheduled release of products
- Logistics & Distribution: Provides comprehensive logistics and distribution services
- Product Promotion: Offers promotional services to enhance product visibility and market reach.
Hualan Biological Engineering
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of research, development, production, and commercialization of human blood products, vaccines, monoclonal antibody, and genetic recombination biologics, achieving significant innovation and market impact in China's biopharmaceutical industry.
- Key Products:
- Plasma Products: High-quality human blood plasma for medical use
- Viral Vaccines: Development and production of vaccines for viral diseases
- Bacterial Vaccines: Production of vaccines for bacterial infections
- Monoclonal Antibodies: Research and development of therapeutic monoclonal antibodies
- Genetic Recombination Biologics: Production and commercialization of genetically engineered biologics